Propionate de sodium

On the basis of region, the market is segmented into North America, South America, Europe, Asia-Pacific and the Middle East & Africa. The sodium propionate market in Asia Pacific was valued at US$ Mn in 2014, which is expected to increase to US$ Mn by 2021. The market in Asia Pacific has very few small capacity producers of sodium propionate and the region majorly depends on imports to meet demand. China and India are emerging as leading producers in the region and are targeting emerging markets of Southeast and South Asia by providing cost-effective products.  

Although patients receiving systemic corticosteroid therapy are more susceptible to secondary infection than patients not receiving corticosteroids, administration via the inhaled route minimizes this risk. Corticosteroid therapy can mask the symptoms of infection and should not be used in cases of bacterial, fungal, or viral infections that are not adequately controlled by anti-infective agents, except in life-threatening circumstances. Fluticasone; salmeterol should be avoided in patients with tuberculosis infections of the respiratory tract if possible. The incidence or course of acute bacterial or viral infection is probably minimally affected by inhaled corticosteroids in immunocompetent individuals; however, close monitoring of patients with immunosuppression is recommended if treatment with an inhaled corticosteroid is necessary.

Propionate de sodium

propionate de sodium


propionate de sodiumpropionate de sodiumpropionate de sodiumpropionate de sodiumpropionate de sodium